Doctors Note Logo

Published on: 10/1/2026

When the polio vaccine was invented, and which one you probably had

Jonas Salk's inactivated polio vaccine (IPV) was licensed in 1955, and Albert Sabin's oral polio vaccine (OPV) followed in 1961 and 1962, so which one you received depends largely on where and when you were born. In the United States, most people vaccinated between the early 1960s and 1999 got the oral drops, while anyone vaccinated from 2000 onward received the injected IPV, and some children in the 1990s got a mixed schedule of both. Several factors affect your personal history, including your birth year, country, and how many doses you completed, so see below to understand which applies to you.

If you are trying to piece this together because of new symptoms such as muscle weakness, fatigue, joint pain, or trouble swallowing, guessing is rarely useful and waiting can delay answers. Take a free, instant, online symptom check to see what your symptoms may point to and get clear guidance on your next steps.

Last reviewed for medical accuracy: 10/01/2026

answer background

Explanation

When Was the Polio Vaccine Invented and Which One You Probably Had

Polio, or poliomyelitis, was once a common and feared disease, especially among children. Thanks to vaccines, it’s now close to global eradication. Understanding when the polio vaccine was invented and which version you likely received can help you appreciate this public health triumph.

A Brief History of Polio and Early Vaccine Efforts

Before vaccines, polio epidemics struck every few years, causing paralysis or death in thousands. Scientists raced to find a way to stop the virus.

  • 1908: Polio virus identified by Karl Landsteiner and Erwin Popper.
  • 1930s–1940s: Initial attempts at killed-virus vaccines in animals showed promise.
  • World War II: Advances in growing the virus in laboratory cell cultures accelerated research.

When Was the Polio Vaccine Invented?

The answer involves two key milestones:

  1. Inactivated Polio Vaccine (IPV) – Salk Vaccine

    • Invented by Dr. Jonas Salk.
    • Announced on April 12, 1955, after large-scale field trials involving 1.3 million children (the “Polio Pioneers”).
    • Uses killed (inactivated) virus to build immunity without causing disease.
  2. Oral Polio Vaccine (OPV) – Sabin Vaccine

    • Developed by Dr. Albert Sabin.
    • Licensed for use in the early 1960s (U.S. approval in 1961).
    • Contains live, weakened virus taken by mouth, producing strong intestinal immunity.

These two vaccines remain the foundation of polio prevention worldwide.

How the Two Vaccines Work

Both vaccines train the immune system, but in slightly different ways:

  • IPV (Salk)

    • Delivered by injection.
    • Induces strong blood immunity, preventing virus from reaching the nervous system.
    • Very safe, with virtually no risk of causing polio.
  • OPV (Sabin)

    • Taken orally (drops under the tongue).
    • Induces both blood and gut immunity, blocking virus spread in communities.
    • Rare risk (< 1 case per 2.7 million doses) of vaccine-derived poliovirus in under-immunized populations.

Which Polio Vaccine You Probably Had

Your age and country of residence determine which vaccine you received.

  • If you were born in the United States after 2000, you almost certainly got IPV (Salk):

    • U.S. shifted entirely to IPV in 2000 to eliminate the small OPV risk.
    • Standard schedule: four IPV doses at 2 months, 4 months, 6–18 months, and 4–6 years of age.
  • If you were born in the U.S. between 1963 and 2000, you likely received a combination of OPV and IPV:

    • OPV was the primary vaccine from 1963 until the switch in 2000.
    • Some infants got IPV early, then OPV for community immunity.
  • If you grew up in other countries, vaccine type varied:

    • Many low- and middle-income countries still use OPV for its ease and low cost.
    • Some countries now use a combination schedule (IPV + OPV) to maximize safety and herd immunity.

Why Two Vaccines?

Each vaccine has strengths that complement the other:

  • IPV is extremely safe and ideal for long-term protection in polio-free areas.
  • OPV is easy to administer, highly effective at halting transmission, and suitable for mass immunization drives.

Global polio eradication efforts often begin with OPV in regions at risk of outbreaks and then transition to IPV as cases decline.

Impact of the Polio Vaccine

Since the 1950s, polio cases have dropped by more than 99%:

  • 350,000 cases worldwide in 1988.
  • Fewer than 200 reported cases in 2020.
  • Only two countries (Afghanistan and Pakistan) still report wild poliovirus.

This success is one of the greatest achievements in public health history.

Safety and Side Effects

Polio vaccines are among the safest vaccines available. Common mild side effects may include:

  • Soreness or redness at the injection site (IPV).
  • Temporary fever, sore throat, or mild stomach upset (OPV).

Severe reactions are extremely rare. The benefits of polio vaccination—preventing paralysis and death—far outweigh these minor risks.

The Path to Eradication

To finish the job of polio eradication, health organizations focus on:

  • High vaccination coverage in every community.
  • Rapid outbreak response with mass vaccination campaigns.
  • Surveillance of sewage systems and cases of acute flaccid paralysis.

Keeping polio at zero worldwide requires continued vigilance until the virus is gone for good.

What If You Have Concerns Today?

Even though polio is rare, other conditions can cause muscle weakness or fever. If you or your child experiences worrying symptoms:

Final Thoughts

  • When was the polio vaccine invented? The Salk vaccine debuted in 1955, followed by Sabin’s oral vaccine in 1961.
  • You probably had IPV if you grew up in the U.S. after 2000, or a mix of IPV and OPV if earlier.
  • Both vaccines changed the course of history, slashing polio cases by over 99%.

Vaccination remains the best protection against polio and many other serious diseases. Staying up to date with recommended vaccines is a simple way to safeguard your health and that of your community.

(References)

  • * Meldrum M. "A calculated risk": the Salk polio vaccine field trials of 1954. BMJ. 1998 Oct 31;317(7167):1233-6. doi: 10.1136/bmj.317.7167.1233. PMID: 9794869; PMCID: PMC1114166.

  • * REPORT on development of polio vaccine. Phys Ther Rev (1948). 1953 Nov;33(11):603-4. PMID: 13120362.

  • * NATHANSON N, LANGMUIR AD. THE CUTTER INCIDENT. POLIOMYELITIS FOLLOWING FORMALDEHYDE- INACTIVATED POLIOVIRUS VACCINATION IN THE UNITED STATES DURING THE SPRING OF 1955. I. BACKGROUND. Am J Hyg. 1963 Jul;78:16-28. doi: 10.1093/oxfordjournals.aje.a120327. PMID: 14043543.

  • * NATHANSON N, LANGMUIR AD. THE CUTTER INCIDENT. POLIOMYELITIS FOLLOWING FORMALDEHYDE- INACTIVATED POLIOVIRUS VACCINATION IN THE UNITED STATES DURING THE SPRING OF 1955. II. RELATIONSHIP OF POLIOMYELITIS TO CUTTER VACCINE. Am J Hyg. 1963 Jul;78:29-60. doi: 10.1093/oxfordjournals.aje.a120328. PMID: 14043545.

  • * FERGUSON JK. THE STORY OF POLIOMYELITIS VACCINES. Can J Public Health. 1964 May;55:183-90. PMID: 14161448.

  • * MAYER L. ORTHOPAEDIC ADVANCES OF THE LAST 50 YEARS AND THE PROBLEMS WE OF THE OLDER GENERATION HAND OVER TO THE YOUNGER FOR SOLUTION. Bull Hosp Joint Dis. 1964 Apr;25:11-20. PMID: 14216088.

  • * Báguena Cervellera MJ. [Epidemiological and virological studies into the poliomyelitis in Valencia (1959-1969)]. Asclepio. 2009;61(1):39-54. doi: 10.3989/asclepio.2009.v61.i1.271. PMID: 19750610.

  • * Martínez-Pérez J. [Consolidating the medical model of disability: on poliomyelitis and constitution of orthopedic surgery and orthopaedics as a speciality in Spain (1930-1950)]. Asclepio. 2009;61(1):117-42. doi: 10.3989/asclepio.2009.v61.i1.274. PMID: 19753686.

  • * Ali D, Banda R, Mohammed A, Adagadzu J, Murele B, Seruyange R, Makam J, Mkanda P, Okpessen B, Tegegne SG, Folorunsho AS, Erbeto TB, Yehualashet YG, Vaz RG. Strengthening Routine Immunization in Areas of Northern Nigeria at High Risk for Polio Transmission During 2012-2014. J Infect Dis. 2016 May 1;213 Suppl 3(Suppl 3):S147-50. doi: 10.1093/infdis/jiv580. Epub 2016 Feb 24. PMID: 26917576; PMCID: PMC4818556.

  • * Velázquez-Arellano A. [A forgotten chapter of Mexican technology and science: Luis Gutiérrez Villegas and poliomyelitis in Mexico]. Gac Med Mex. 2017;153(5):633-640. doi: 10.24875/GMM.17003060. PMID: 29099101.

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.